Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

B of A Securities Upgrades Helmerich & Payne to Neutral

B of A Securities analyst Chase Mulvehill upgrades Helmerich & Payne (NYSE:HP) from Underperform to Neutral.
byBenzinga Newsdesk
July 16, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

B of A Securities analyst Chase Mulvehill upgrades Helmerich & Payne (NYSE:HP) from Underperform to Neutral.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38

By Charles Gross
Today, 10:35 AM
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission rate(a) (based

JNJ